<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600219</url>
  </required_header>
  <id_info>
    <org_study_id>AHD2020</org_study_id>
    <nct_id>NCT04600219</nct_id>
  </id_info>
  <brief_title>The Effect of Tyrosine Kinase Receptor Axl on Dialysis Prognosis in Chronic Hemodialysis Patients</brief_title>
  <official_title>The Effect of Tyrosine Kinase Receptor Axl on Dialysis Prognosis in Chronic Hemodialysis Patients: a Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ai Peng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether tyrosine kinase receptor Axl affects the&#xD;
      dialysis prognosis in chronic hemodialysis patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is reported that hemodialysis (HD) patients often develop chronic systemic inflammatoion,&#xD;
      and increased inflammatory activity is associated with vascular access failure,&#xD;
      cardiovascular disease and death in HD patients. The interaction of Axl and its ligand Gas6&#xD;
      plays an important role in modulating immune response, inhabiting toll-like receptor (TLR)&#xD;
      signaling and suppressing inflammatory cytokines production. Thus, we want to investigate the&#xD;
      relationship between tyrosine kinase receptor Axl and the dialysis prognosis in HD patients&#xD;
      in three-years follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>3 years</time_frame>
    <description>death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>dialysis complication</measure>
    <time_frame>3 years</time_frame>
    <description>vascular access failure, stroke, acute coronary syndrome, heart failure</description>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Hemodialysis Complication</condition>
  <eligibility>
    <study_pop>
      <textblock>
        End-stage renal disease patients undergoing hemodialysis treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  hemodialysis for more than 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients who received warfarin therapy;&#xD;
&#xD;
          -  patients with chronic infectious disease or acute infection;&#xD;
&#xD;
          -  patients with hemodialysis inadequacy;&#xD;
&#xD;
          -  the age of patients is older than 65 years or younger than 18 years.&#xD;
&#xD;
          -  patients who can not sign an informed consent or disagree to follow up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ai Peng, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai 10th People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nephrology &amp; Rheumatology, Shanghai Tenth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200272</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>November 1, 2020</last_update_submitted>
  <last_update_submitted_qc>November 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Ai Peng</investigator_full_name>
    <investigator_title>Director of the department of Nephrology,Shanghai 10th people's hospital</investigator_title>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>Axl</keyword>
  <keyword>prognosis</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

